Loading
Every dated change on the records linked to Extensive-stage small-cell lung cancer, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Maintenance with atezolizumab in ES-SCLC after first-line induction; 29 May 2026
Untreated extensive-stage small-cell lung cancer, with carboplatin and etoposide
ES-SCLC after platinum-based chemotherapy; 29 May 2026
Met the primary overall survival endpoint at the pre-specified interim analysis (Amgen, 8 September 2026); progression-free survival and response rate also improved; figures not yet disclosed.
Untreated extensive-stage small-cell lung cancer, with etoposide and either carboplatin or cisplatin
First-line maintenance with atezolizumab in ES-SCLC (full approval)
First-line ES-SCLC with carboplatin-etoposide
Extensive-stage small-cell lung cancer progressing after two or more lines of treatment including platinum-based chemotherapy: not recommended
OS HR 0.
OS 13.
A milestone in how this cancer is treated.
Untreated extensive-stage small-cell lung cancer, with carboplatin and etoposide
Objective response 35.
A milestone in how this cancer is treated.
Median overall survival 11.
A milestone in how this cancer is treated.
Symptomatic brain metastases at 1 year 14.
A milestone in how this cancer is treated.